BRPI0919853B8 - anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ao receptor de interleucina-4 humano (hil-4r) e seus usos - Google Patents

anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ao receptor de interleucina-4 humano (hil-4r) e seus usos

Info

Publication number
BRPI0919853B8
BRPI0919853B8 BRPI0919853A BRPI0919853A BRPI0919853B8 BR PI0919853 B8 BRPI0919853 B8 BR PI0919853B8 BR PI0919853 A BRPI0919853 A BR PI0919853A BR PI0919853 A BRPI0919853 A BR PI0919853A BR PI0919853 B8 BRPI0919853 B8 BR PI0919853B8
Authority
BR
Brazil
Prior art keywords
receptor
antibody
hil
antigen
binding fragment
Prior art date
Application number
BRPI0919853A
Other languages
English (en)
Inventor
L Fairhurst Jeanette
H Martin Joel
J Papadopoulos Nicholas
T Huang Tammy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41600767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0919853(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BRPI0919853A2 publication Critical patent/BRPI0919853A2/pt
Publication of BRPI0919853B1 publication Critical patent/BRPI0919853B1/pt
Publication of BRPI0919853B8 publication Critical patent/BRPI0919853B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

anticorpos humanos de alta afinidade para receptor il-4 humano, método para produzi-los, seus usos, sequência de ácidos nucléicos, vetor e sistema vetor-hospedeiro. a presente invenção refere-se a um fragmento de anticorpo ou anticorpo humano isolado dos mesmos que se liga ao receptor de interleucina-4 humano alfa (hll-4r (alfa) com alta afinidade (k0), capaz de bloquear a atividade hll-4 e hll-13.
BRPI0919853A 2008-10-29 2009-10-27 anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ao receptor de interleucina-4 humano (hil-4r) e seus usos BRPI0919853B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/260,307 2008-10-29
US12/260,307 US7608693B2 (en) 2006-10-02 2008-10-29 High affinity human antibodies to human IL-4 receptor
PCT/US2009/062168 WO2010053751A1 (en) 2008-10-29 2009-10-27 High affinity human antibodies to human il-4 receptor

Publications (3)

Publication Number Publication Date
BRPI0919853A2 BRPI0919853A2 (pt) 2016-03-15
BRPI0919853B1 BRPI0919853B1 (pt) 2020-10-27
BRPI0919853B8 true BRPI0919853B8 (pt) 2021-05-25

Family

ID=41600767

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919853A BRPI0919853B8 (pt) 2008-10-29 2009-10-27 anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ao receptor de interleucina-4 humano (hil-4r) e seus usos

Country Status (47)

Country Link
US (7) US7608693B2 (pt)
EP (7) EP3064511B1 (pt)
JP (8) JP5291802B2 (pt)
KR (1) KR101599706B1 (pt)
CN (3) CN102197052B (pt)
AR (1) AR073978A1 (pt)
AU (1) AU2009311496B9 (pt)
BR (1) BRPI0919853B8 (pt)
CA (1) CA2737044C (pt)
CL (1) CL2009002004A1 (pt)
CO (1) CO6362024A2 (pt)
CR (1) CR20110148A (pt)
CY (3) CY1114123T1 (pt)
DK (3) DK2356151T3 (pt)
EC (1) ECSP11011010A (pt)
ES (4) ES2802241T3 (pt)
FI (1) FI3715372T3 (pt)
FR (1) FR18C1011I2 (pt)
HN (1) HN2011001210A (pt)
HR (3) HRP20240492T1 (pt)
HU (3) HUE066473T2 (pt)
IL (1) IL211726A (pt)
JO (1) JO2865B1 (pt)
LT (3) LT3064511T (pt)
LU (1) LUC00059I2 (pt)
MA (1) MA32802B1 (pt)
MX (3) MX388436B (pt)
MY (1) MY152448A (pt)
NI (1) NI201100064A (pt)
NL (1) NL300922I2 (pt)
NO (2) NO2018009I2 (pt)
NZ (2) NZ591922A (pt)
PA (1) PA8847001A1 (pt)
PE (1) PE20100738A1 (pt)
PH (1) PH12014500462A1 (pt)
PL (4) PL3064511T3 (pt)
PT (4) PT3351560T (pt)
RS (3) RS57522B1 (pt)
RU (2) RU2539774C3 (pt)
SI (3) SI2356151T1 (pt)
SM (2) SMT201800362T1 (pt)
SV (1) SV2011003880A (pt)
TW (3) TW201919700A (pt)
UA (1) UA102122C2 (pt)
UY (1) UY32213A (pt)
WO (1) WO2010053751A1 (pt)
ZA (1) ZA201101867B (pt)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763249B2 (en) * 2004-04-27 2010-07-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid β peptide antibody and fragment of said antibody
LT2769992T (lt) 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
HRP20151188T4 (hr) 2010-02-08 2021-10-01 Regeneron Pharmaceuticals, Inc. Miš sa zajedničkim lakim lancem
UA111731C2 (uk) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
CN106267189B (zh) * 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
PT2796550T (pt) * 2011-12-22 2018-04-18 Astellas Pharma Inc Novo anticorpo ctgf anti-humano
KR102213535B1 (ko) 2012-03-16 2021-02-08 리제너론 파마슈티칼스 인코포레이티드 pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
DK2825036T3 (en) 2012-03-16 2018-07-16 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents to generate them
TR201819492T4 (tr) * 2012-08-21 2019-01-21 Regeneron Pharma Bir ıl-4r antagonisti uygulayarak astımı tedavi etmek veya önlemek için yöntemler.
IL312711A (en) * 2012-08-21 2024-07-01 Regeneron Pharma Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
KR102284244B1 (ko) * 2012-09-07 2021-08-03 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
KR102576903B1 (ko) * 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
HRP20191709T1 (hr) * 2013-06-21 2019-12-13 Sanofi Biotechnology Postupci liječenja nosne polipoze davanjem antagonista il-4r
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
IL247290B (en) * 2014-02-21 2021-06-30 Sanofi Biotechnology Methods of treating or preventing asthma by adding an il-4r antagonist
KR102927870B1 (ko) 2014-02-28 2026-02-19 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
NO2785538T3 (pt) 2014-05-07 2018-08-04
CN107206068A (zh) 2014-07-16 2017-09-26 赛诺菲生物技术公司 用于治疗杂合型家族性高胆固醇血症(heFH)患者的方法
WO2016077675A1 (en) 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP6938383B2 (ja) 2015-04-02 2021-09-22 インターベット インターナショナル ベー． フェー． イヌインターロイキン４受容体アルファに対する抗体
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
AU2017220184B2 (en) 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
CN113372446A (zh) * 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
KR20190053250A (ko) 2016-09-22 2019-05-17 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
JP7321939B2 (ja) 2017-04-13 2023-08-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
BR112020000127A2 (pt) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
EP3703818B1 (en) 2017-10-30 2023-11-01 Sanofi Biotechnology Il-4r antagonist for use in a method for treating or preventing asthma
BR112020010615A2 (pt) 2017-12-22 2020-10-27 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, método e sistema para caracterizar impurezas de produto farmacêutico proteico e de fármaco de baixo peso molecular, método para produzir um anticorpo, anticorpo, e, usos do método e do sistema
MX2020008095A (es) 2018-01-31 2020-09-24 Regeneron Pharma Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
WO2019148405A1 (zh) * 2018-02-01 2019-08-08 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
CN110105451B (zh) * 2018-02-01 2020-12-18 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
KR20200127979A (ko) 2018-02-28 2020-11-11 리제너론 파마슈티칼스 인코포레이티드 바이러스 오염물질을 확인하기 위한 시스템 및 방법
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
CA3246952A1 (en) 2018-03-19 2025-10-31 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
EP3768317A4 (en) * 2018-03-22 2021-12-22 Surface Oncology, Inc. ANTI-IL-27 ANTIBODIES AND USES THEREOF
CN108373505B (zh) * 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
CN113101364B (zh) * 2018-05-29 2023-12-01 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制剂的开发和应用
AR115730A1 (es) * 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
BR112021002989A2 (pt) 2018-08-24 2021-05-11 Jiangsu Hengrui Medicine Co., Ltd. anticorpo para ligação de il-4r de humano, fragmento para ligação de antígeno e uso médico do mesmo
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
CN113166259A (zh) * 2018-11-09 2021-07-23 亚洲大学校产学协力团 对人IL-4受体α具有高亲和力的人抗体及其用途
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN111494625B (zh) * 2018-12-25 2022-06-21 江苏荃信生物医药股份有限公司 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物
PL3857237T3 (pl) 2019-01-16 2023-07-10 Regeneron Pharmaceuticals, Inc. Sposoby charakteryzowania mostka disiarczkowego
AU2020231343B2 (en) 2019-03-06 2026-03-26 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
AU2020275406A1 (en) 2019-05-13 2021-11-18 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
CN112010977B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 抗白介素4受体(il-4r)的抗体及其应用
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
CA3147436A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
IL291020B2 (en) 2019-09-24 2025-04-01 Regeneron Pharma Systems and methods for use in chromatography and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
MY207613A (en) 2019-11-25 2025-03-06 Regeneron Pharma Sustained release formulations using non-aqueous emulsions
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
MX2022007677A (es) 2019-12-20 2022-07-19 Intervet Int Bv Anticuerpos para receptor alfa de interleucina-4 canino.
US11835527B2 (en) 2020-01-21 2023-12-05 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
JP7752620B2 (ja) 2020-02-21 2025-10-10 江蘇恒瑞医薬股▲ふん▼有限公司 抗ｉｌ－４ｒ抗体医薬組成物及びその使用
BR112022017174A2 (pt) * 2020-02-27 2022-10-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
KR20220158821A (ko) 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
IL298257A (en) 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
IL300828A (en) 2020-08-31 2023-04-01 Regeneron Pharma Asparagine feeding strategies to improve cell culture performance and reduce asparagine sequence variants
MX2023003942A (es) 2020-10-05 2023-06-02 Sanofi Biotechnology Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
US12350374B2 (en) 2020-12-17 2025-07-08 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
US20240075158A1 (en) * 2020-12-22 2024-03-07 Jiangsu Hengrui Pharmaceutical Co., Ltd. Complex of anti-il-4r antibody or antigen-binding fragment thereof and medical use thereof
MX2023007945A (es) 2021-01-08 2023-09-21 Regeneron Pharma Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
AR125585A1 (es) 2021-03-03 2023-08-02 Regeneron Pharma Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
CA3211302A1 (en) 2021-03-26 2022-09-29 Ross Kenyon Methods and systems for developing mixing protocols
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
WO2023009437A1 (en) 2021-07-26 2023-02-02 Sanofi Biotechnology Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
TWI876192B (zh) * 2021-08-05 2025-03-11 美商美國禮來大藥廠 人類介白素-4受體α抗體
US20230235069A1 (en) 2021-08-10 2023-07-27 Kymab Limited Treatment of atopic dermatitis
KR20240049351A (ko) 2021-08-23 2024-04-16 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
US20240343815A1 (en) * 2021-08-26 2024-10-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pharmaceutical composition of anti-il4r antibody and use thereof
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
CA3232463A1 (en) * 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
CA3230302A1 (en) 2021-09-30 2023-04-06 Regeneron Pharmaceuticals, Inc. Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
JP2024538673A (ja) 2021-10-07 2024-10-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ｐＨモデリング及び制御のシステム及び方法
US20230183362A1 (en) 2021-10-20 2023-06-15 Sanofi Biotechnology Methods for treating prurigo nodularis by administering an il-4r antagonist
MX2024005090A (es) 2021-10-26 2024-07-19 Regeneron Pharma Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
WO2023086887A1 (en) 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
WO2023085978A1 (en) * 2021-11-11 2023-05-19 Joint Stock Company «Biocad» Monoclonal antibody or antigen-binding fragment thereof that specifically binds to il-4ra, and use thereof
EP4433085A2 (en) * 2021-11-18 2024-09-25 Twist Bioscience Corporation Dickkopf-1 variant antibodies and methods of use
MX2024006518A (es) 2021-11-30 2024-06-11 Regeneron Pharma Tratamiento de la enfermedad pulmonar basado en la estratificacion de la puntuacion poligenica en relacion con la respuesta a un agente terapeutico.
CN118355034A (zh) 2021-12-30 2024-07-16 瑞泽恩制药公司 施用il-4/il-13拮抗剂以减弱特应性进程的方法
JP2025508665A (ja) 2022-01-29 2025-04-10 上海盛迪医薬有限公司 グルココルチコイドの薬物複合体
JP2025507790A (ja) 2022-03-02 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高力価抗体のための製造プロセス
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
CA3259540A1 (en) 2022-07-08 2024-01-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist
WO2024047021A1 (en) 2022-08-29 2024-03-07 Sanofi Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist
KR20240038841A (ko) 2022-09-16 2024-03-26 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이의 용도
CN120187754A (zh) 2022-11-01 2025-06-20 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗手足皮炎的方法
EP4622669A1 (en) 2022-11-23 2025-10-01 Regeneron Pharmaceuticals, Inc. Methods for improving bone growth by administering an il-4r antagonist
CN120418653A (zh) 2022-12-16 2025-08-01 里珍纳龙药品有限公司 评估色谱柱完整性的方法和系统
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
KR20250150541A (ko) * 2023-02-17 2025-10-20 아포지 테라퓨틱스, 인크. 인터류킨 4 수용체 알파에 결합하는 항체 및 사용 방법
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
EP4683942A1 (en) 2023-03-22 2026-01-28 Sanofi Biotechnology Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
CN121001741A (zh) 2023-03-27 2025-11-21 瑞泽恩制药公司 用于通过施用il-4r拮抗剂治疗嗜酸粒细胞性胃肠炎的方法
EP4687971A1 (en) 2023-03-30 2026-02-11 Sandoz Ag Stable composition comprising a high protein concentration
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
KR20240170605A (ko) 2023-05-23 2024-12-04 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이를 포함하는 비강 분무 제형
AU2024315507A1 (en) 2023-07-28 2026-02-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing antibody-drug conjugate of glucocorticoid
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
CN121925272A (zh) 2023-09-29 2026-04-24 瑞泽恩制药公司 利用受控成核进行冻干
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
AU2024373307A1 (en) 2023-11-02 2026-05-14 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
US20250179207A1 (en) 2023-11-30 2025-06-05 Genzyme Corporation Methods for treating digitally-identified cd20-related disorders
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
CN117924490B (zh) * 2023-12-22 2024-10-22 华润生物医药有限公司 抗il-4r抗体及其用途
WO2025166234A1 (en) * 2024-01-31 2025-08-07 Apogee Therapeutics, Inc. Methods of administering antibodies that bind interleukin 4 receptor alpha
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
EP4623903A1 (en) 2024-03-28 2025-10-01 Fresenius Kabi Deutschland GmbH Pharmaceutical composition comprising dupilumab
TW202607027A (zh) 2024-04-15 2026-02-16 法商賽諾菲生物技術公司 藉由施用ｉｌ－４ｒ拮抗劑治療慢性鼻竇炎不伴鼻息肉之方法
US20260008857A1 (en) * 2024-06-13 2026-01-08 Flagship Pioneering Innovations Vi, Llc Antigen Binding Molecules Targeting Interleukine-4 Receptor Subunit Alpha (IL-4Ra)
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
US20260070995A1 (en) 2024-09-09 2026-03-12 Marcella Ruddy Methods for treating bullous pemphigoid by administering an il-4r antagonist
WO2026059949A1 (en) 2024-09-10 2026-03-19 Sanofi Biotechnology Methods for treating chronic pruritus of unknown origin (cpuo) by administering an il-4r antagonist
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
BR9205967A (pt) * 1991-05-03 1994-07-26 Seragen Inc Moléculas marcadas com receptor de interleucina tratamento de artrite inflamatória
DE69321218T2 (de) * 1992-02-19 1999-02-18 Schering Corp., Kenilworth, N.J. Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) * 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
ZA946875B (en) * 1993-09-07 1995-07-06 Smithkline Beecham Corp Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US6387632B2 (en) * 1998-06-11 2002-05-14 Hitachi, Ltd. Polynucleotide separation method and apparatus therefor
AU766492B2 (en) 1998-09-18 2003-10-16 Dynavax Technologies Corporation Methods of treating IgE-associated disorders and compositions for use therein
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
WO2001092340A2 (en) 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
AU2001267917A1 (en) 2000-07-26 2002-02-05 Kenjirou Tsuchida Antipruritic compositions and compositions promoting wound healing
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
RU2283665C2 (ru) 2000-12-22 2006-09-20 Сосьете Де Продюи Нестле С.А. Индуцирование толерантности
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US20050031609A1 (en) 2001-05-11 2005-02-10 Thomas Hultsch Compositions for use in treating ige-associated disorders
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
AU2002357770B2 (en) 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1592777A4 (en) 2003-02-01 2008-06-04 Tanox Inc METHOD OF GENERATING HIGH-ANTIBODY ANTIBODIES
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
NZ547588A (en) 2003-11-07 2009-05-31 Immunex Corp Antibodies that bind interleukin-4 receptor
CA2550933A1 (en) * 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
EP1723173B1 (en) 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypeptides and therapeutic uses thereof
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
WO2006083390A2 (en) 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
TW200902555A (en) 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
TW200804593A (en) 2006-01-24 2008-01-16 Domantis Ltd Fusion proteins that contain natural junctions
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
LT2769992T (lt) 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
US8637239B2 (en) 2007-11-05 2014-01-28 The Board Of Trustees Of The University Of Illinois Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
DK2245064T3 (da) 2007-12-21 2014-10-27 Medimmune Ltd BINDINGSELEMENTER TIL INTERLEUKIN-4-RECEPTOR-ALFA (IL-4Ralfa)
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
US20110301046A1 (en) 2008-12-01 2011-12-08 Children's Hospital Medical Center Methods of Determining Efficacy of Glucocorticoid Treatment of Eosinophilic Esophagitis
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
BR112012005117A2 (pt) 2009-09-07 2016-05-03 Dbv Tech método de tratamento de esofagite eosinofílica
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
ES2894936T3 (es) 2010-06-24 2022-02-16 Viropharma Biologics Llc Métodos de tratamiento para la inflamación del esófago
CN106267189B (zh) * 2010-10-06 2021-02-26 瑞泽恩制药公司 含有抗白介素-4受体(il-4r)的抗体的稳定制剂
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
WO2012094643A2 (en) 2011-01-06 2012-07-12 Children's Hospital Medical Center Esophageal cytokine expression profiles in eosinophilic esophagitis
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
EP2723899B1 (en) 2011-06-21 2020-11-18 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US20140303067A1 (en) 2011-10-06 2014-10-09 N.V. Nutricia Treatment of eosinophilic esophagitis
KR20140113667A (ko) 2011-12-16 2014-09-24 아토픽스 테라퓨릭스 리미티드 호산구성 식도염의 치료를 위한 ｃｒｔｈ2 길항제 및 양성자 펌프 저해제의 조합
US20130243750A1 (en) 2012-01-31 2013-09-19 Genentech, Inc. Anti-ige antibodies and methods using same
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
IL312711A (en) * 2012-08-21 2024-07-01 Regeneron Pharma Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
KR102576903B1 (ko) 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
US9963513B2 (en) 2013-02-05 2018-05-08 Engmab Sàrl Method for the selection of antibodies against BCMA
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
KR102927870B1 (ko) 2014-02-28 2026-02-19 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
WO2016077675A1 (en) * 2014-11-14 2016-05-19 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
AU2017220184B2 (en) 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
KR20190053250A (ko) 2016-09-22 2019-05-17 리제너론 파아마슈티컬스, 인크. Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
JP2020507605A (ja) 2017-02-17 2020-03-12 フレッド ハッチンソン キャンサー リサーチ センター Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
EP3703818B1 (en) 2017-10-30 2023-11-01 Sanofi Biotechnology Il-4r antagonist for use in a method for treating or preventing asthma
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
EP4010373A1 (en) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
AU2020325021B2 (en) 2019-08-05 2024-05-30 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
KR20220158821A (ko) 2020-03-27 2022-12-01 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
IL298257A (en) 2020-05-22 2023-01-01 Regeneron Pharma Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
MX2023007945A (es) 2021-01-08 2023-09-21 Regeneron Pharma Metodos para tratar la alergia al cacahuate y mejorar la inmunoterapia especifica de alergeno del cacahuate mediante la administracion de un antagonista de il-4r.

Also Published As

Publication number Publication date
PA8847001A1 (es) 2010-05-26
NO2018009I2 (no) 2019-01-30
RU2011120194A (ru) 2012-12-10
ES2802241T3 (es) 2021-01-18
JP2016041069A (ja) 2016-03-31
SMT201800362T1 (it) 2018-09-13
CR20110148A (es) 2011-04-27
DK2356151T3 (da) 2013-06-17
SI3715372T1 (sl) 2024-05-31
TWI538686B (zh) 2016-06-21
HUE039212T2 (hu) 2018-12-28
JP6608505B2 (ja) 2019-11-20
NI201100064A (es) 2011-11-02
US20100047254A1 (en) 2010-02-25
CY1114123T1 (el) 2016-07-27
JP5844772B2 (ja) 2016-01-20
EP2356151A1 (en) 2011-08-17
DK3715372T3 (da) 2024-03-11
HRP20240492T1 (hr) 2024-07-05
HK1250733A1 (en) 2019-01-11
US20210163611A1 (en) 2021-06-03
US7608693B2 (en) 2009-10-27
EP2636685A1 (en) 2013-09-11
HRP20130467T1 (en) 2013-06-30
EP3064511B1 (en) 2018-04-18
RU2014147773A (ru) 2016-06-20
AU2009311496B9 (en) 2014-10-30
ZA201101867B (en) 2012-08-29
KR101599706B1 (ko) 2016-03-04
LTPA2018002I1 (lt) 2018-02-12
WO2010053751A1 (en) 2010-05-14
RU2663106C2 (ru) 2018-08-01
RS57522B1 (sr) 2018-10-31
JP2020007378A (ja) 2020-01-16
CN103739711B (zh) 2016-09-14
CN102197052A (zh) 2011-09-21
MY152448A (en) 2014-09-30
LUC00059I1 (pt) 2018-01-03
LTC2356151I2 (lt) 2019-04-10
AR073978A1 (es) 2010-12-15
NZ591922A (en) 2012-03-30
DK3064511T3 (en) 2018-07-16
PH12014500462A1 (en) 2015-06-01
ES2675917T3 (es) 2018-07-13
JP2024040526A (ja) 2024-03-25
IL211726A (en) 2015-10-29
EP3715372B1 (en) 2024-01-24
CA2737044C (en) 2017-02-28
TWI658833B (zh) 2019-05-11
EP3064511A1 (en) 2016-09-07
PT3351560T (pt) 2020-05-11
JP2012507294A (ja) 2012-03-29
CY1122092T1 (el) 2020-07-31
UY32213A (es) 2010-05-31
HK1159136A1 (en) 2012-07-27
CY2018003I2 (el) 2018-09-05
US20180179288A1 (en) 2018-06-28
HUE066473T2 (hu) 2024-08-28
EP2511300A3 (en) 2012-11-07
NL300922I2 (nl) 2019-01-15
EP3351560A1 (en) 2018-07-25
PL3715372T3 (pl) 2024-06-24
CN106267190B (zh) 2021-01-26
US20090074793A1 (en) 2009-03-19
MX356882B (es) 2018-06-19
SMT201300074B (it) 2013-09-06
US8735095B2 (en) 2014-05-27
JP7100731B2 (ja) 2022-07-13
US8337839B2 (en) 2012-12-25
SI3064511T1 (en) 2018-08-31
US8075887B2 (en) 2011-12-13
CY2018003I1 (el) 2018-09-05
US12162943B2 (en) 2024-12-10
PT2356151E (pt) 2013-05-07
CN106267190A (zh) 2017-01-04
LT3715372T (lt) 2024-03-25
ES2975006T3 (es) 2024-07-02
AU2009311496B2 (en) 2014-05-29
JP6449125B2 (ja) 2019-01-09
JP7442581B2 (ja) 2024-03-04
HN2011001210A (es) 2013-10-22
EP4345111A2 (en) 2024-04-03
ECSP11011010A (es) 2011-06-30
NO2018009I1 (no) 2018-03-06
EP3715372A1 (en) 2020-09-30
MX388436B (es) 2025-03-20
FI3715372T3 (fi) 2024-03-18
CN102197052B (zh) 2014-02-12
JP7824339B2 (ja) 2026-03-04
US20140271681A1 (en) 2014-09-18
PL2356151T3 (pl) 2013-08-30
JO2865B1 (en) 2015-03-15
IL211726A0 (en) 2011-06-30
PL3351560T3 (pl) 2020-09-21
CA2737044A1 (en) 2010-05-14
MA32802B1 (fr) 2011-11-01
JP2021087440A (ja) 2021-06-10
AU2009311496A1 (en) 2010-05-14
LUC00059I2 (pt) 2018-03-28
JP6843208B2 (ja) 2021-03-17
US20130078675A1 (en) 2013-03-28
FR18C1011I1 (pt) 2018-04-27
TW201919700A (zh) 2019-06-01
EP3351560B1 (en) 2020-04-22
DK3715372T5 (da) 2024-08-26
EP2356151B1 (en) 2013-04-10
HUS1800014I1 (hu) 2018-03-28
RS65385B1 (sr) 2024-04-30
MX2011003346A (es) 2011-04-21
PE20100738A1 (es) 2010-11-03
KR20110074980A (ko) 2011-07-05
NO2023019I1 (no) 2023-05-02
SV2011003880A (es) 2011-08-15
TW201029664A (en) 2010-08-16
PT3064511T (pt) 2018-07-17
US20120052072A1 (en) 2012-03-01
BRPI0919853A2 (pt) 2016-03-15
RU2539774C2 (ru) 2015-01-27
HRP20181148T1 (hr) 2018-09-21
PT3715372T (pt) 2024-03-14
FR18C1011I2 (fr) 2020-03-06
EP2511300A2 (en) 2012-10-17
RU2539774C3 (ru) 2020-11-06
ES2404206T3 (es) 2013-05-24
SI2356151T1 (sl) 2013-07-31
EP4345111A3 (en) 2024-05-22
JP5291802B2 (ja) 2013-09-18
JP2013223495A (ja) 2013-10-31
RS52782B (sr) 2013-10-31
CO6362024A2 (es) 2012-01-20
BRPI0919853B1 (pt) 2020-10-27
UA102122C2 (ru) 2013-06-10
LT3064511T (lt) 2018-07-10
JP2022160404A (ja) 2022-10-19
CN103739711A (zh) 2014-04-23
NZ596093A (en) 2012-11-30
PL3064511T3 (pl) 2018-09-28
CL2009002004A1 (es) 2010-03-05
TW201615216A (zh) 2016-05-01
JP2019055963A (ja) 2019-04-11

Similar Documents

Publication Publication Date Title
Andrews et al. High preexisting serological antibody levels correlate with diversification of the influenza vaccine response
BRPI0800612A2 (pt) método e kit para a quantificação de subclasses de igg humanas especìficas a alérgenos para o acompanhamento da imunoterapia especìfica
MX388436B (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano.
BR112018070823A2 (pt) anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno, composição farmacêutica, produto de combinação, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, polipeptídeo, métodos para fabricar um anticorpo, in vitro ou ex vivo para determinar células positivas para sirpa, de diagnóstico e para prever a resposta de um sujeito, e, uso de um anticorpo anti-sirpa ou um fragmento de ligação a antígeno do mesmo ou um mimético de ligação a anticorpo e in vitro ou ex vivo de pelo menos um anticorpo sirpa anti-humano ou fragmento de ligação a antígeno do mesmo ou mimético de anticorpo de ligação a antígeno.
BRPI0911431B8 (pt) composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo
BR112019005726A8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno
ES2633597T3 (es) Anticuerpos con afinidad modificada para FcRn que promueven la eliminación del antígeno
BR112016014284A2 (pt) anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo
BR112015024553A2 (pt) anticorpo multiespecífico, anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de anticorpo, imunoconjugado, formulação farmacêutica, uso de anticorpo e método de tratamento de indivíduos com distúrbio
BR112015021979A2 (pt) Anticorpos humanos para grem1
NZ701444A (en) Antibodies to matrix metalloproteinase 9
BR112014027465A8 (pt) método de teste in vitro, kit de detecção, usos do kit, método in vitro de diagnóstico e método para fabricar um kit
BR112015023262B8 (pt) Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112012018914A2 (pt) "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica."
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112016016207A2 (pt) Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos
BR112021020426A2 (pt) Anticorpos anti-cd3 dependentes de ph projetados e métodos para sua geração e uso
CR20120359A (es) Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada
BR112017022255A2 (pt) anticorpo humanizado ou humano isolado, molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um anticorpo, e composição farmacêutica
BR112022009602A2 (pt) Anticorpos anti-cd79 ch38c-cd79 chctric, células car-t, e usos dos mesmos
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
BR112013024686A2 (pt) ensaio de psa, e, reagente de ensaio de psa

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF